BioAro Inc. has made a significant advancement in artificial intelligence by introducing the world”s first large language model (LLM) based on unified multi-omics data. This groundbreaking technology, known as The BioIntelligenceTM, aims to interpret the complex interactions among genes, proteins, and metabolites, transforming how we understand human biology. The innovation was announced on October 27, 2025, and will be showcased at the Global Health Exhibition in Riyadh.
The primary challenge in modern medicine is the fragmentation of biological data. Currently, health professionals are inundated with isolated genomic, proteomic, and metabolomic data that tell an incomplete story about health and disease. This disconnection hinders the ability to identify the underlying causes of complex diseases such as cancer and diabetes, ultimately delaying effective treatments. PanOmiQTM, powered by The BioIntelligenceTM, addresses this issue by providing a cohesive understanding of these biological interactions.
“We have moved from counting words to understanding poetry—the poetry written in the language of our own cells,” said Dr. Anmol Kapoor, the founder and CEO of BioAro. “The core of a new health ecosystem is The BioIntelligenceTM. It transforms disconnected data into a coherent dialogue between patients and their own biology, finally making proactive, predictable health a practical reality.”
To ensure the highest security for sensitive genetic data, BioAro has designed PanOmiQTM for on-premises deployment. The platform utilizes a combination of FPGA acceleration and GPU computing to function as a self-contained intelligence unit within hospitals or laboratories. This design not only protects patient data but also enhances the speed and efficiency of data processing.
The BioIntelligenceTM ecosystem includes a suite of specialized tools that work together seamlessly. The AxionTM Series comprises a proprietary range of intelligent hardware systems designed to deliver on-premises, FPGA-accelerated AI computation tailored for healthcare and research environments. With versions designed for various operational needs, the AxionTM line—Core, Ultra, and Supreme—offers hospitals and research institutes the capability to deploy advanced technology securely and effectively.
Bader Al-Marzooqi, a prominent Emirati health-tech investor, emphasized the significance of this solution for the UAE and the Gulf region. “BioAro isn”t just importing technology; they are delivering a sovereign capability that aligns with our national vision for a secure, innovative, and proactive healthcare future,” he stated. “It empowers our clinicians while protecting our citizens” data.”
During the Global Health Exhibition in Riyadh, BioAro plans to showcase the capabilities of its ecosystem, including a live demonstration with GenelioTM and real-time multi-omics analysis through PanOmiQTM. “We are not just launching a product; we are igniting a movement—from reactive guesswork to proactive, intelligent health,” Dr. Kapoor added. “The future of medicine speaks the language of life itself, and we are proud to give it a voice in Riyadh.”
BioAro Inc., headquartered in Canada, is dedicated to revolutionizing intelligent, sovereign health solutions. The company”s mission focuses on unifying biology and data science, bridging the gap between complex molecular information and actionable, personalized health insights.
